Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02489448
Title Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Yale University
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Nab-paclitaxel

Cyclophosphamide + Doxorubicin

Age Groups: adult
Covered Countries USA


No variant requirements are available.